687 related articles for article (PubMed ID: 25030653)
1. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?
Sapir-Koren R; Livshits G
Osteoporos Int; 2014 Dec; 25(12):2685-700. PubMed ID: 25030653
[TBL] [Abstract][Full Text] [Related]
2. Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications.
Yan Y; Wang L; Ge L; Pathak JL
Curr Osteoporos Rep; 2020 Feb; 18(1):67-80. PubMed ID: 31953640
[TBL] [Abstract][Full Text] [Related]
3. [Bone and Nutrition. Sclerostin and bone metabolism].
Tatsumi S; Nagamoto K; Ogata M; Miyamoto K
Clin Calcium; 2015 Jul; 25(7):1043-7. PubMed ID: 26119318
[TBL] [Abstract][Full Text] [Related]
4. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
[TBL] [Abstract][Full Text] [Related]
5. SOST gene suppression stimulates osteocyte Wnt/β-catenin signaling to prevent bone resorption and attenuates particle-induced osteolysis.
Jiao Z; Chai H; Wang S; Sun C; Huang Q; Xu W
J Mol Med (Berl); 2023 May; 101(5):607-620. PubMed ID: 37121919
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
[TBL] [Abstract][Full Text] [Related]
7. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
Allison H; Holdsworth G; McNamara LM
BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
[TBL] [Abstract][Full Text] [Related]
8. The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.
Spatz JM; Wein MN; Gooi JH; Qu Y; Garr JL; Liu S; Barry KJ; Uda Y; Lai F; Dedic C; Balcells-Camps M; Kronenberg HM; Babij P; Pajevic PD
J Biol Chem; 2015 Jul; 290(27):16744-58. PubMed ID: 25953900
[TBL] [Abstract][Full Text] [Related]
9. [Osteocytes and Wnt signaling.].
Fukumoto S
Clin Calcium; 2019; 29(3):317-321. PubMed ID: 30814376
[TBL] [Abstract][Full Text] [Related]
10. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
11. The Function of Wnt Ligands on Osteocyte and Bone Remodeling.
Du JH; Lin SX; Wu XL; Yang SM; Cao LY; Zheng A; Wu JN; Jiang XQ
J Dent Res; 2019 Jul; 98(8):930-938. PubMed ID: 31282847
[TBL] [Abstract][Full Text] [Related]
12. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.
Tu X; Rhee Y; Condon KW; Bivi N; Allen MR; Dwyer D; Stolina M; Turner CH; Robling AG; Plotkin LI; Bellido T
Bone; 2012 Jan; 50(1):209-17. PubMed ID: 22075208
[TBL] [Abstract][Full Text] [Related]
13. Osteocytes and WNT: the mechanical control of bone formation.
Galli C; Passeri G; Macaluso GM
J Dent Res; 2010 Apr; 89(4):331-43. PubMed ID: 20200416
[TBL] [Abstract][Full Text] [Related]
14. The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases.
Pathak JL; Bravenboer N; Klein-Nulend J
Front Endocrinol (Lausanne); 2020; 11():405. PubMed ID: 32733380
[TBL] [Abstract][Full Text] [Related]
15. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
[TBL] [Abstract][Full Text] [Related]
17. Mechanobiological osteocyte feedback drives mechanostat regulation of bone in a multiscale computational model.
Martin M; Sansalone V; Cooper DML; Forwood MR; Pivonka P
Biomech Model Mechanobiol; 2019 Oct; 18(5):1475-1496. PubMed ID: 31087221
[TBL] [Abstract][Full Text] [Related]
18. Regulatory mechanisms of sclerostin expression during bone remodeling.
Koide M; Kobayashi Y
J Bone Miner Metab; 2019 Jan; 37(1):9-17. PubMed ID: 30357564
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
[TBL] [Abstract][Full Text] [Related]
20. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
